Long-Term Liabilities: The sum of all non-current liabilities.
Karyopharm Therapeutics Inc. (KPTI) had Long-Term Liabilities of $309.28M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$146.07M |
|
$-196.04M |
|
$5.95M |
|
$140.12M |
|
$236.77M |
|
$-90.71M |
|
$-105.29M |
|
$-196.00M |
|
$-196.00M |
|
$-196.04M |
|
$-196.04M |
|
$-196.04M |
|
$-196.04M |
|
$-90.71M |
|
$-80.28M |
|
10.94M |
|
10.94M |
|
$-17.93 |
|
$-17.93 |
|
| Balance Sheet Financials | |
$103.15M |
|
$0.10M |
|
$5.27M |
|
$108.42M |
|
$92.06M |
|
$205.88M |
|
|
Long-Term Liabilities |
$309.28M |
$401.34M |
|
$-292.93M |
|
$-292.93M |
|
$-292.93M |
|
18.31M |
|
| Cash Flow Statement Financials | |
$-75.37M |
|
$43.38M |
|
$30.05M |
|
$62.81M |
|
$60.89M |
|
$-1.92M |
|
$14.05M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.12 |
|
-- |
|
-- |
|
-2.37 |
|
-0.77 |
|
95.93% |
|
-62.10% |
|
-62.10% |
|
-54.96% |
|
-134.18% |
|
-134.21% |
|
$-75.37M |
|
-- |
|
-- |
|
-- |
|
1.35 |
|
1.47 |
|
5.58 |
|
65.42 |
|
66.92% |
|
66.92% |
|
-180.82% |
|
225.23% |
|
$-16.00 |
|
$-6.89 |
|
$-6.89 |
|